cawd-176,欧美 性爱 国产 综合,亚洲国产黄色在线,庆余年在线观看免费
中文簡體
中文簡體
English
HOME
ABOUT US
Company Profile
Company Culture
Company Honor
R&D
Technology Platform
Pipelines
NEWS
Press Release
Awards
CAREERS
CONTACT US
中文簡體
中文簡體
English
Search
/uploads/image/img/banner-txt-en-03.svg
首頁
-
NEWS
Press Release
Awards
Press Release
Awards
Beihai Biotech announced that its innovative cancer drug, BH009 (marketed as BEIZRAY), has received approval from the U.S. Food and Drug Administration (FDA)
2024-10-31
U.S. FDA Formally Accepts Beihai Biotech's New Drug Application for Innovative Oncology Drug BH009 (BEIZRAY?)
2024-01-04
Beihai Biotech Founder Dr. Sun Invited to Keynote 'Wisdom in China' Summit at Renmin University Business School
2023-12-26
Beihai Biotech Successfully Concludes Series C Funding, Expediting BH009 Commercialization and Advancing Clinical Trials for Innovative Drug Candidates
2023-12-19
Beihai Biotech Listed Among "Top 100 High-Growth Enterprises in the Greater Bay Area 2023"
2023-11-09
Innovation Recognized Again: Beihai Biotech Honored with GHP “Most Innovative Clinical-Stage Biopharmaceutical Company 2023”
2023-08-01
Beihai Biotech Secures “Drug Manufacturing Certificate”
2023-06-15
Landmark Clinical Research Findings of Beihai Biotech's BH009 Unveiled at ASCO 2023
2023-06-12
<<
1
2
3
4
5
>>
ABOUT US
R&D
NEWS
CAREERS
CONTACT US
Contact Information
Company address:Blg 2, No. 6366, Zhuhai Ave., Jinwan, Zhuhai, 519090, China
Tel:0756-6349669
Human resources contact:hr@bayhibiotech.com
Business cooperation contact:hjiang@bayhibiotech.com
Wechat Official Account
Copyright ? 2023 Zhuhai Beihai Biotech Co., Ltd.
Copyright Registration No. :
Guangdong ICP for 17134092
Technical support :
Xiangxun Technology